HARBIN, China, July 23 /PRNewswire-Asia-FirstCall/ — China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People’s Republic of China (“PRC”), today announced that the Company has obtained approval from the State Food and Drug Administration (SFDA) in China for the production of Ciclopirox Olamine Vaginal Suppositories. The document number for this drug is H20103320.
Ciclopirox Olamine Vaginal Suppositories were developed by CSKI’s internal R&D team based on registration standards of similar imported drugs. The drug’s main ingredient, Ciclopirox Olamine, is a synthetic broad-spectrum antibacterial that has been proven effective in clinical studies for treatment of fungal vaginal infections (candida albicans vaginitis) and fungal vaginal inflammation (colpits mycotica). It can resist or restrain most pathogenic streptomyces, including skin fungus and candida albicans as well as many kinds of nonpathogenic streptomyces, gram negative bacilli and gram positive bacilli. The drug is a good treatment option for partial infection as it is minimally absorbed by the skin.
“We greatly appreciate the dedicated efforts of our R&D and sales teams to bring new drugs like Ciclopirox Olamine Vaginal Suppositories to market,” said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. “We expect to launch this product in early 2011 and plan on gaining share in this large market by leveraging our extensive distribution network and strong OTC pharmaceutical sales force.”
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (“TDR”), Harbin First Bio-Engineering Company Limited (“First”), Heilongjiang Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
China Sky One Medical, Inc.
Yan-qing Liu, CEO
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Ms. Mabel Zhang, Vice President
SOURCE China Sky One Medical, Inc.